

# Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Marta Chesi<sup>1</sup>, Elena Nardini<sup>2</sup>, Leslie A. Brents<sup>1</sup>, Evelin Schröck<sup>3</sup>, Thomas Ried<sup>3</sup>, W. Michael Kuehl<sup>1</sup> & P. Leif Bergsagel<sup>2</sup>

**Dysregulation of oncogenes by translocation to the IgH locus (14q32) is a seminal event in the pathogenesis of B-cell tumours<sup>1</sup>. In multiple myeloma (MM), translocations to the IgH locus have been reported at an incidence of 20–60%. For most translocations, the partner chromosome is unknown (14q+); for the others, a diverse array of chromosomal partners have been identified, with 11q13 (cyclin D1) the only chromosome that is frequently involved<sup>2–6</sup>. Recently, we developed a Southern-blot assay that detects translocation breakpoint fragments in most MM tumours, including those with no translocation detected by conventional karyotyping<sup>6</sup>. In a continuing analysis of translocations in 21 myeloma cell lines and primary tumours, we show that the novel, karyotypically silent translocation t(4;14)(p16.3;q32.3) is present in five lines and at least three of ten primary tumours. The chromosome-4 breakpoints are clustered in a 70-kb region centromeric to the fibroblast growth factor receptor 3 gene (*FGFR3*), the apparent dysregulated oncogene. Two lines and one primary tumour with this translocation selectively express an *FGFR3* allele containing activating mutations identified previously in thanatophoric dwarfism. We propose that after the t(4;14) translocation, somatic mutation during tumour progression frequently generates an *FGFR3* protein that is active in the absence of ligand.**


As described in detail elsewhere<sup>6</sup>, we generated paired probes immediately upstream and downstream of the repetitive sequences in each switch region—for example, 5'S $\mu$  and 3'S $\mu$  probes. By Southern-blot analysis, candidate translocation breakpoint fragments were identified as rearranged fragments that hybridize to only one switch probe. Fig. 1a illustrates a balanced translocation into S $\mu$ , with the 3'S $\mu$  probe detecting the der(14) breakpoint and the 5'S $\mu$  probe detecting the der(4) breakpoint. Using this approach, we cloned one translocation breakpoint fragment involving chromosome 4 from each of five samples: four MM lines (KMS11, H929, OPM2 and JIM3) and one plasma cell leukaemia tumour (PCL-1). In each case, the novel non-Ig sequences at the breakpoint and at one end of the fragment were identical to sequences present in a cosmid contig that is centromeric to the fibroblast growth factor receptor 3 (*FGFR3*) gene at 4p16.3 (Fig. 1)<sup>7</sup>. Having the published sequence of the entire breakpoint region, we designed specific primer pairs to PCR-amplify probes that were used in Southern-blot analyses to detect and map reciprocal breakpoint fragments for KMS11, H929 and PCL-1 (Fig. 2a–c). For example, as shown in Fig. 2a for the der(4)(5'S $\mu$ ) reciprocal breakpoint in KMS11

(Fig. 1), a 5'S $\mu$  probe detected a rearranged 7.9-kb *Xba*I fragment (compared to 7.5-kb fragment in placental [P] DNA) and a 4p16.3 probe (9226 in Fig. 1b) that detects a 13.8-kb germline fragment in the tumour and in placental DNA, co-hybridizes to the 7.9-kb *Xba*I fragment in KMS11. These results, together with Southern blots using other enzymes, are consistent with the der(4) (5'S $\mu$ ) translocation breakpoint occurring near the cloned der(14) (3'S $\mu$ ) translocation breakpoint for KMS11 (Fig. 1b).

We used an RT-PCR assay to screen for expression of *FGFR3*. A prominent band (Fig. 3a) was detected in three lines (KMS11, OPM2 and H929) and one primary tumour (PCL-1) with cloned t(4;14)(p16.3;q32.3) translocation breakpoints, and also in one additional line (UTMC2). Eight MM lines (8226, ARK, SKMM1, DELTA47, H1112, KMM1, TH and U266) generated barely detectable PCR products (data not shown). The remaining nine lines (ANBL6, FLAM76, SKMM2, JIM3, JIN3, KMS12, MM-M1, MM.1-144 and MY5) were completely negative for *FGFR3* expression by this assay. In addition, a similar PCR analysis of nine intramedullary MM samples, together with normal peripheral blood and bone marrow samples, showed amplification of *FGFR3* from cDNA in three intramedullary MM samples (MM.T0, MM.T1 and MM.T2; Fig. 3a and data not shown) but not in normal bone marrow or blood cells. Overexpression of *FGFR3* by the MM cell lines was confirmed by northern blot and immunoprecipitation analyses. As seen in Fig. 3b, an intense 4.5-kb *FGFR3* mRNA<sup>8</sup> is present at extremely high levels in KMS11 and OPM2, at much lower levels in H929 and at barely detectable levels in UTMC2. The protein analysis (Fig. 3c) demonstrates the expected 115- and 135-kD *FGFR3* protein species<sup>9</sup> at levels concordant with the levels of mRNA. As assessed by northern and western blots, respectively, there was no detectable *FGFR3* mRNA or protein in the other MM cell lines examined, including those that showed a barely detectable signal by the RT-PCR assay.

On the basis of the *FGFR3* expression data, we looked for evidence of translocation t(4;14)(p16.3;q32.3) in the UTMC2 MM cell line (Fig. 2d). We detected a rearranged 8.6-kb *Xba*I fragment that co-hybridizes with a 5'S $\mu$  probe and the chromosome-4 probe 9213, and a rearranged 17.3-kb *Sph*I fragment that co-hybridizes with a 3'S $\mu$  probe and the chromosome-4 probe 9226—that is, the der(4) (5'S $\mu$ ) and der(14) (3'S $\mu$ ) reciprocal breakpoints (Fig. 1). This translocation was confirmed in UTMC2 by two-colour FISH analysis (Fig. 4). We also identified the t(4;14) translocation by mapping its presence in the *FGFR3*-expressing tumour samples MM.T1 and MM.T2 (data not shown).

<sup>1</sup>Genetics Department, Medicine Branch, National Cancer Institute, Bethesda, Maryland 20889-5105, USA. <sup>2</sup>Department of Medicine, Division of Hematology and Oncology, Cornell University Medical College, New York NY, 10021, USA. <sup>3</sup>Diagnostic Development Branch, National Center for Human Genome Research, National Institutes of Health, Bethesda, Maryland 20892-4470, USA. Correspondence should be addressed to W.M.K. e-mail: wmk@helix.nih.gov




**Fig. 1** Translocation breakpoints involving 4p16.3. **a**, Diagram of der(14) and der(4) breakpoints resulting from a translocation into S $\mu$ . The centromere is to the left, and the figure is not to scale. Structural elements include enhancers (3'E and 5'E), switch region (S $\mu$ ) and coding segments (C $\mu$  and JH). Thick horizontal lines depict 3'- and 5'S $\mu$  probes. Vertical lines represent restriction enzyme sites, X = XbaI, H = HindIII, S = SphI. **b**, Distribution of 4p16.3 breakpoints within the distal 70 kb of a 2-Mb cosmid contig spanning the Huntington's disease region, centromeric to the *FGFR3* gene. The diagram is drawn to scale. Solid arrows indicate the positions of the cloned breakpoints for the OPM2, JIM3, H929 and KMS11 myeloma cell lines and for the tumour sample (PCL-1), while a dashed arrow shows where the breakpoints for UTMC2 have been mapped by Southern-blot analysis. Next to each arrow is indicated the type and orientation of the switch region associated with the breakpoint; the shaded designation indicates breakpoints determined by Southern blotting. The sites of restriction enzymes, indicated by a capital letter (H for HindIII, S for SphI, X for XbaI), as well as the position of the probes, indicated by thick lines, used for cloning the breakpoint or for Southern-blot analysis are depicted in

the enlarged sections. The entire sequence (except for three short gaps in L75b9) of the most distal cosmid contig (L190b4, L184d6 and L75b9) in the Huntington's disease region is known. The transcription orientation of *FGFR3* gene is from the T7 end to the T3 end of pC385.12 (M.R. Alther, pers. comm.).

Although the translocation t(4;14)(p16.3;q32.3) has not been described previously, the results reported here suggest that it occurs with an incidence of about 25% in MM. Conventional karyotypic analysis of the PCL-1 tumour and the five cell lines in which we have identified the translocation t(4;14), failed to detect this translocation, although JIM3 was reported to have a 14q+ translocation. These results are consistent with our recent finding that karyotypically silent translocations to the IgH locus occur frequently in MM<sup>6</sup>. In addition, this translocation is not a cell-line artifact, as we have confirmed the presence of the translocation breakpoint in

six primary tumour samples: PCL-1, MM.T1, MM.T2 and the corresponding tumours of three (JIM3, H929 and UTMC2) of the five MM lines with this translocation (data not shown).



Dominant, activating mutations in different domains of *FGFR3* are implicated in dwarfism, including (in order of increasing severity) hypochondroplasia, achondroplasia and thanatophoric dysplasia type I and II (TDI-II)<sup>10-13</sup>. We used RT-PCT SSCP analysis to screen for *FGFR3* mutations in all twelve MM cell lines (KMS11, OPM2, H929, UTMC2, H1112, TH, KMM1, 8226, ARK, SKMM1, Delta 47 and U266) and five tumour samples (JIM3-T, PCL-1,



**Fig. 2** Identification of chromosomal rearrangements affecting the 4p16.3 locus. Southern blots were performed on 10  $\mu$ g of DNA from three MM cell lines (KMS11 in **a**, H929 in **b**, and UTMC2 in **d**), from a tumour sample (PCL-1 in **c**) and from placenta (P). The DNA was digested with the indicated restriction enzyme and hybridized sequentially with the switch and the chromosome 4p16.3 probes listed below each line. Arrows identify the rearranged bands that co-hybridize with the switch and chromosome 4p16.3 probes as a consequence of the translocations t(4;14)(p16;q32). Additional bands not seen in placental DNA or designated by the arrow represent other rearrangements unrelated to the translocation; for instance, the 15-kb band detected by the 3'S $\alpha$  probe in H929 (**b**) identifies a productive  $\mu$  to  $\alpha$  switch recombination event. It should be noted that the absence or altered migration of germline bands in some of the samples (for example, UTMC2 probed with 5'S $\mu$ , **2d**) is due to multiple kinds of switch recombination events (for example, translocation, productive rearrangement), genetic polymorphisms, or deletion. We refer only to the bands related to the t(4;14) translocation products.

MM.T0, MM.T1 and MM.T2) that express *FGFR3* mRNA. For example, as shown in Fig. 3d, KMS11 contains wild-type and variant alleles but expresses only the variant allele, which was found to contain a Y373C [A1157G] mutation. Missense mutations of *FGFR3* were also identified in the OPM2 cell line (K650E [A1987G]) and in the MM.T1 primary tumour (K650M [A1988T]), both of which have t(4;14) translocations. Each of these missense mutations occurs in thanatophoric dysplasia<sup>14-16</sup>; for one of them (K650E), the constitutive activation of *FGFR3* in the absence of ligand has been proved by transfection experiments<sup>11,12</sup>.

Although we cannot exclude the possibility that other genes are dysregulated by the translocation t(4;14) in MM, we have identified the *FGFR3* gene as an apparent oncogene that is dysregulated by this translocation into an IgH switch region. First, the *FGFR3* gene is localized no more than about 100 kb from the most centromeric breakpoint at 4p16.3, and is located on the der(14) chromosome that contains the 3' IgH enhancer(s) but not the intronic enhancer (Fig. 1a). This is similar to the situation for cyclin D1, which is localized 100-400 kb from the breakpoint in the translocation t(11;14)(q13;q32.3) that occurs in mantle-cell lymphoma and MM tumours<sup>5,17-19</sup>. Second, *FGFR3* mRNA is overexpressed in all but one cell line (JIM3) with the translocation t(4;14), but primary tumour cells (JIM3-T) from the excepted line do express *FGFR3* mRNA (Fig. 3a). It is possi-



**Fig. 3** Expression of *FGFR3* in MM. **a**, RT-PCR assay: a fragment of 598 bp has been amplified from four MM cell lines (UTMC2, KMS11, H929 and OPM2) and four tumour samples (PCL-1, JIM3-T, MM-T1 and MM-T2) by 35 cycles with a primer pair specific for the 3' half of the second immunoglobulin-like domain and the juxta-membrane (JM) region of the *FGFR3* gene. **b**, Northern-blot assay: Poly(A)<sup>+</sup> RNA from 100 µg of total RNA from six MM cell lines was fractionated on an agarose gel, blotted, and then hybridized sequentially with *FGFR3* and  $\beta$ -actin probes. After five hours of exposure, the 4.5 kb-band corresponding to *FGFR3* mRNA was detected in OPM2, H929 and KMS11, whereas a much longer exposure (63 hours) was needed for detection in UTMC2. **c**, Immunoblotting detection of *FGFR3*. Protein lysates from five MM cell lines were immunoprecipitated with a polyclonal rabbit antiserum against *FGFR3*. The immune complexes were separated on a 7.5% polyacrylamide SDS gel, blotted and detected with the same antiserum. Specific bands of 115 and 135 kD were detected in all four MM cell lines positive both by RT-PCR and northern-blot analysis. **d**, Selective expression of an *FGFR3* variant allele in KMS11 by SSCP analysis. A primer pair flanking the juxta-membrane and transmembrane region of *FGFR3* generate a 164-bp fragment by PCR from KMS11 genomic DNA and cDNA, and from placental genomic DNA (P). The products were then labelled with <sup>32</sup>P-dCTP, denatured and fractionated on a native 10% polyacrylamide gel, and detected by autoradiography. The informative region of the gel is shown.

ble that the translocation in JIM3 was initially associated with dysregulated expression of *FGFR3*, but that silencing of this gene occurred during tumour evolution after another genetic event that eliminated the need for *FGFR3* expression. Conversely, all MM lines that overexpress *FGFR3* have a translocation t(4;14). It was somewhat surprising to us that the level of expression of *FGFR3* mRNA or protein in the UTMC2 line is approximately 30 times lower than found for the KMS11 line, even though Southern blotting indicates no amplification of the *FGFR3* gene in any of the lines with a translocation (data not shown). However, consistent with this extreme variability in expression (Fig. 3c), the expression of *c-myc* in Burkitt lymphoma lines that have an t(8;14) translocation can vary over an approximately 100-fold range (M. Zajac-Kaye, personal communication). Third, two cell lines (KMS11, OPM2) and two tumours (PCL.1, MM.T1) contain two genetically distinguishable *FGFR3* alleles, but each selectively expresses one allele, as predicted if the translocation is responsible for dysregulation of *FGFR3* (Fig. 3 and data not shown). Fourth, the variant, missense alleles in KMS11, OPM2 and MM.T1 must result from a somatic mutation, since these mutations in the germline cause thanatophoric dysplasia<sup>14-16</sup>, the most severe form of dwarfism, which results in fetal or neonatal death. The activating mutations of *FGFR3* seem to occur frequently in MM—that is,

**Fig. 4** Two-colour fluorescence *in situ* hybridization of the UTMC2 MM line with *FGFR3* and chromosome-14 probes. The chromosome-14 probe generates a red signal, whereas other chromosomes are stained blue. The *FGFR3* cosmid clone, located on chromosome band 4p16, generates green and yellow signals, respectively, on chromosomes that are counterstained blue and red. The *FGFR3* cosmid clone hybridized to the telomeric band of two chromosomes 4 (normal map position) and to the telomeric band of two chromosomes 14 [translocation t(4;14)(p16;q32)]. The other two chromosomes 14 showed only the hybridization signal of the chromosome 14-specific painting probe.

two of five lines and one of three primary tumours in which we have identified a t(4;14) translocation by cloning or mapping. We suggest that the translocation t(4;14) occurred at an early stage of tumorigenesis, and the subsequent mutation in the dysregulated *FGFR3* gene during tumour progression contributed to ligand independent growth. Finally, FGFs have been shown to have different effects on cell growth, survival and differentiation, depending on the cell type<sup>20</sup>. More specifically, *FGFR3* can transduce signals that either inhibit or stimulate cell proliferation. For example, *FGFR3* inhibits proliferation of chondrocytes in normal individuals or excessively inhibits growth of chondrocytes in individuals that have *FGFR3* alleles with activating mutations<sup>21-23</sup>. Alternatively, it has been shown that an IL3-dependent lymphoid cell line expressing a transfected *FGFR3* gene can be mitogenically stimulated by FGFs plus heparin in the absence of IL3 (ref. 24). It has been postulated by others that growth and/or survival of MM cells is mediated by interaction with bone marrow stromal cells<sup>25</sup>. We propose that dysregulated expression of *FGFR3* provides a continuous oncogenic signal for MM cells juxtaposed to stromal cells that are known to express FGFs<sup>26</sup>.

## Methods

**Cell culture.** Human MM cell lines, as described in detail previously, were grown in Petri dishes in RPMI 1640 medium supplemented with 10% fetal calf serum<sup>6</sup>. For three cell lines, we obtained corresponding primary tumour cells—that is, pleural effusion cells for the JIM3 (JIM3-T), H929 and UTM2 cell lines. Primary tumour samples reported previously include PCL.1 and MM.T0, corresponding to patient #1 and patient #2, respectively<sup>6</sup>. Additional intramedullary MM tumor specimens are designated MM.T1 to MM.T8.

**Cosmid clones.** L190b4, L184d6, L75b9, pWC385.31 and pC385.12 cosmids were kindly provided to us by M.R. Altherr, Los Alamos National Laboratory.

**Translocation breakpoint fragments.** The cloned chromosome 4 translocation breakpoint fragments included a 7.6-kb *HindIII* fragment detected with a 3' S $\mu$  probe (KMS11); 2.0-kb (OPM2) and 3.8-kb (JIM3) *HindIII* fragments detected with a 3' S $\nu$  probe; and 4.0-kb *SphI* (H929) and 2.6-kb *HindIII* (PCL-1) fragments detected with a 5' S $\mu$  probe.

**Isolation and characterization of PAC184d6/385.** A PAC human genomic library (Genome Systems) was screened with a telomeric L75b9 probe (#9295, 237 bp) PCR amplified using the following primers: 5'-TTGCTGTCCCGTAAAGTTGCTAAG-3' and 5'-TCTGCTATTGTGATACCGCATGAC-3' (56 °C). A single clone was obtained, and its two ends were sequenced. The SP6 end overlaps L184d6 by 5 kb, whereas the telomeric T7 end has no homology to known sequences and does not overlap any of the cosmids in this region. Sequence from the T3 and T7 ends of pC385.12 (which contains the *FGFR3* gene) enabled us to make primer pairs for each end of the insert (5'-GATATTGCGGAAGATACTAAGGC-3' and 5'-GTAAGTGGGTCTCACTATGTTGC-3'; 5'-CAGACAATACTAAACCGAGCTTTC-3' and 5'-CGCTGCCTCAATCTATGCTCTCAG-3'). These primers were used in a PCR assay to demonstrate that both ends of the pC385.12 insert are contained in the PAC clone, while only the T3 end overlaps the pC385.31 cosmid clone. The *FGFR3* gene appears to be located approximately 100 kb telomeric to the most centromeric OPM2 translocation breakpoint.

**Primers and probes.** Switch region probes upstream (for example, 5'S $\mu$ ) and downstream (for example, 3'S $\nu$ ) of the repetitive sequences in each switch region were generated. The sequence of PCR primers used to amplify these probes is reported elsewhere<sup>6</sup>, with the exception of the 5'S $\mu$  probe (260 bp), which was amplified with the following primers: 5'-GGGACCTGCTCATTTTATC-3' and 5'-TCAGCTAAAGCCATCTCATTGCC-3'

(56 °C). The 9037 probe was a 211-bp fragment PCR amplified from L184d6 cosmid with the following primers: 5'-CTTGCTTGA-CAACGTCAGGCTAC-3' and 5'-ACCTGGCTGAGGAGACAGTAA-GTG-3' (56 °C). The 9213 (151 bp), 9226 (328 bp) and 9330 (264 bp) probes were PCR amplified from L75b9 cosmid by 5'-TGCAGTAAAGTC-CTCACTTACCAAC-3' and 5'-CACAACCTGATGGTGGTTCAAATC-3' (61 °C), 5'-CTGCTGCATGTACCTGGCTAAAG-3' and 5'-TGCTGGGAA-GTATGATGAAGGAAG-3' (61°C), 5'-CTTAGTGTCTGCTCGAGCTTT-3' and 5'-ACAACCTCAACCCATACAGGGG-3' (59 °C), respectively: the *FGFR3* probe used in the northern-blot assay was a PCR amplified 262-bp fragment, extending from the middle of exon IIIC to the middle of the transmembrane-spanning domain<sup>27</sup>. The  $\beta$ -actin probe was a 2.0-kb *BamHI* rabbit cDNA fragment. Information regarding the oligonucleotides used to generate PCR fragments from *FGFR3* cDNA or genomic DNA for SSCP analysis are available on request.

**RT-PCT assays.** The efficiency of cDNA synthesis was monitored by measuring incorporation of labelled dCTP, and the quality of the cDNA was also verified by PCR amplification of an 804-bp *c-myc* fragment (except for cell line U266, which does not express *c-myc* mRNA). An RT-PCT assay, utilizing the primer pairs described by Johnston *et al.*<sup>28</sup> and 10 ng of cDNA, was used to assess the expression of the exon IIIB and IIIC alternatively spliced forms of *FGFR3* mRNA, both of which showed similar patterns of expression. Product was detected by ethidium bromide staining of a 2% agarose gel after 30 to 40 cycles, and also by hybridization with an internal oligonucleotide probe (5'-GAGTCCAACGCGTCCATGAGC-3') to detect product blotted from a gel after 23 cycles.

**Immunoprecipitation and immunoblotting.** Ten million cells were harvested and lysed in RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10  $\mu$ g/ml aprotinin, 1 mM sodium orthovanadate), and 2.5 mg of the total proteins obtained was immunoprecipitated with antiserum specific for the C-terminus of *FGFR3* (Santa Cruz Biotechnology). The immune complexes were collected on protein A/G PLUS-Agarose beads (Santa Cruz Biotechnology), washed extensively, electrophoresed through a 7.5% SDS-PAGE gel and transferred to nitrocellulose. The filter was incubated with anti-*FGFR3* antiserum and horseradish peroxidase-conjugated goat anti-rabbit IgG (Amersham) and developed with the ECL system (Amersham).

**Fluorescence *in situ* hybridization.** Metaphase chromosome preparation, chromosome-14 painting probe generation, hybridization and detection protocols are described elsewhere<sup>29</sup>. The pC385.12 cosmid, containing the entire *FGFR3* gene, was labelled by nick-translation and is localized to 4p16.3.

**Other procedures.** Construction of genomic libraries, screening, isolation and sequencing of recombinant clones, Southern and northern blot analysis<sup>5</sup>, RT-PCT and SSCP analysis<sup>30</sup> are described elsewhere<sup>31</sup>.

**GenBank accession numbers for translocation breakpoint sequences.** U73660 for JIM3, U73661 for PCL-1, U73662 for H929, U73663 for KMS11 and AF006657 for OPM2.

## Acknowledgements

We are indebted to Dr. S. Kirby for providing the PCL.1 primary tumour sample, and to Drs. I.A. Kirsch, I. MacLennan and A. Solomon for providing primary tumour material corresponding to the H929, JIM3 and UTM2 MM cell lines, respectively. Finally, we would like to thank M. R. Altherr (Los Alamos National Laboratory) for providing materials and for helpful discussion about *FGFR3* mapping, and the many investigators who supplied multiple myeloma cell lines. This work was supported in part by generous contributions from the Dorothy Rodbell Cohen Foundation and the Melvin Savin Memorial Fund.

Received 18 November 1996; accepted 24 March 1997.

1. Korsmeyer, S.J. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. *Annu. Rev. Immunol.* **10**, 785–807 (1992).
2. Taniwaki, M. et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. *Blood* **84**, 2283–2290 (1994).
3. Sawyer, J.R., Waldron, J.A., Jagannath, S. & Barlogie, B. Cytogenetic findings in 200 patients with multiple myeloma. *Cancer Genet. Cytogenet.* **82**, 41–49 (1995).
4. Lai, J.L. et al. Improved cytogenetics in multiple-myeloma—a study of 151 patients including 117 patients at diagnosis. *Blood* **85**, 2490–2497 (1995).
5. Chesi, M., et al. Dysregulation of Cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. *Blood* **88**, 674–681 (1996).
6. Bergsagel, P.L. et al. Promiscuous translocations into IgH switch regions in multiple myeloma. *Proc. Natl. Sci. Acad. USA* **93**, 13931–13936 (1996).
7. Baxendale, S. et al. A cosmid contig and high resolution restriction map of the 2 megabase region containing the Huntington's disease gene. *Nature Genet.* **4**, 181–186 (1993).
8. Keegan, K., Johnson, D., William, L.T. & Hayman, M.J. Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3. *Proc. Natl. Acad. Sci. USA* **88**, 1095–1099 (1991).
9. Keegan, K., Meyer, S. & Hayman, M.J. Structural and biosynthetic characterization of the fibroblast growth factor receptor 3 (FGFR-3) protein. *Oncogene* **6**, 2229–2236 (1991).
10. Muenke, M. & Schell, U. Fibroblast-growth-factor-receptor mutations in human skeletal disorders. *Trends Genet.* **11**, 308–313 (1995).
11. Naski, M.C., Wang, Q., Xu, J. & Ornitz, D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. *Nature Genet.* **13**, 233–237 (1996).
12. Webster, M.K., D'Avis, P.Y., Robertson, S.C. & Donoghue, D.J. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. *Mol. Cell. Biol.* **16**, 4081–4087 (1996).
13. Webster, M.K. & Donoghue, D.J. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia. *EMBO J.* **15**, 520–527 (1996).
14. Rousseau, F. et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). *Hum. Mol. Genet.* **5**, 509–512 (1996).
15. Francomano, C.A. et al. A new skeletal dysplasia with severe tibial bowing, profound developmental delay and acanthosis nigricans is caused by a Lys 650 Met mutation in fibroblast growth factor receptor 3 (FGFR3). *Am. J. Hum. Genet.* **59**, A25 (1996).
16. Tavormina, P.L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. *Nature Genet.* **9**, 321–328 (1995).
17. Williams, M.E., Swerdlow, S.H. & Meeker, T.C. Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster. *Leukemia* **7**, 1437–1440 (1993).
18. Tsujimoto, Y. et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. *Nature* **315**, 340–343 (1985).
19. de Boer, C.J. et al. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin D1 gene. *Cancer Res.* **53**, 4148–4152 (1993).
20. Mason, I.J. The ins and outs of fibroblast growth factors. *Cell* **78**, 547–552 (1994).
21. Su, W.S. et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. *Nature* **386**, 288–292 (1997).
22. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. *Nature Genet.* **12**, 390–397 (1996).
23. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. *Cell* **84**, 911–921 (1996).
24. Ornitz, D.M. & Leder, P. Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3. *J. Biol. Chem.* **267**, 16305–16311 (1992).
25. Caligaris-Cappio, F. et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. *Blood* **77**, 2688–2693 (1991).
26. Allouche, M. Basic fibroblast growth factor and hematopoiesis. *Leukemia* **9**, 937–942 (1995).
27. Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. *Cell* **78**, 335–342 (1994).
28. Johnston, C.L., Cox, H.C., Gomm, J.J. & Coombes, R.C. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. *J. Biol. Chem.* **270**, 30643–30650 (1995).
29. Schröck, E. et al. Multicolor spectral karyotyping of human chromosomes. *Science* **273**, 494–497 (1996).
30. Kuehl, W.M., Brents, L.A., Chesi, M. & Bergsagel, P.L. Selective expression of one c-myc allele in two human myeloma cell lines. *Cancer Res.* **56**, 4370–4373 (1996).
31. Davis, L.G., Kuehl, W.M. & Batteny, J.F. *Basic Methods in Molecular Biology* (Appleton & Lange, Norwalk, Connecticut, 1994).